Literature DB >> 19941992

Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine.

Erin R Shanahan1, Rachel Pinto, James A Triccas, Warwick J Britton, Nicholas P West.   

Abstract

Infection with Mycobacterium tuberculosis continues to be a leading cause of death in many regions of the world, and control of this disease is hampered by the lack of a safe and effective vaccine. Secreted proteins of M. tuberculosis are an important group of antigens for subunit vaccines which target this infection. We have tested three secreted members of the cutinase-like protein (CULP) family of M. tuberculosis for their potential as protein vaccine antigens. Culp6 elicited a strong T lymphocyte response in M. tuberculosis infected mice, and importantly, in tuberculosis (TB) patients tested. Culp1, Culp2 and Culp6 when delivered as protein vaccines to mice, induced potent IFN-gamma responses which in turn translated into a significant level of protection against aerosol M. tuberculosis infection. A Culp1-6 fusion protein provided an increased level of protection against infection compared to Culp1 or Culp6 alone. The data presented here may indicate that the cell wall-associated, putatively essential protein Culp6, shown here for the first time to be recognised in TB patients, is an attractive candidate for inclusion in future subunit vaccines. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941992     DOI: 10.1016/j.vaccine.2009.11.010

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

Review 2.  Bacterial Sphingomyelinases and Phospholipases as Virulence Factors.

Authors:  Marietta Flores-Díaz; Laura Monturiol-Gross; Claire Naylor; Alberto Alape-Girón; Antje Flieger
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

3.  A Novel Actinobacterial Cutinase Containing a Noncatalytic Polymer-Binding Domain.

Authors:  Kofi Abokitse; Stephan Grosse; Hannes Leisch; Christopher R Corbeil; Florence Perrin-Sarazin; Peter C K Lau
Journal:  Appl Environ Microbiol       Date:  2021-10-27       Impact factor: 5.005

4.  The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice.

Authors:  Fan F Kao; Sultana Mahmuda; Rachel Pinto; James A Triccas; Nicholas P West; Warwick J Britton
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

5.  TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals.

Authors:  Owais Mohammad; Jagdeep Kaur; Gurpreet Singh; Syed Mohd Faisal; Asim Azhar; Mohd Ahmar Rauf; Umesh Dutt Gupta; Pushpa Gupta; Rahul Pal; Swaleha Zubair
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

6.  Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice.

Authors:  Claudio Counoupas; Rachel Pinto; Gayathri Nagalingam; Grant A Hill-Cawthorne; Carl G Feng; Warwick J Britton; James A Triccas
Journal:  NPJ Vaccines       Date:  2016-09-15       Impact factor: 7.344

7.  Use of Soluble Extracellular Regions of MmpL (SERoM) as Vaccines for Tuberculosis.

Authors:  Emily J Strong; Nicholas P West
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.